Ian Moore
Fortuna: 77 744 $ al 30/06/2026
Fortuna: 77 744 $ al 30/06/2026
Ian Roger Moore served as the Chairman of Novo Nordisk Pharma Ltd. from 2005 to 2007.
He also worked as an Independent Non-Executive Director at Proteomics International Laboratories Ltd. from 2016 to 2024.
Additionally, he was a Member-Management Board at Novo Nordisk A. Mr. Moore completed his undergraduate degree at The University of Sydney.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 08/11/2024 | 975.824 ( 0,59 % ) | 77 744 $ | 30/06/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| PROTEOMICS INTERNATIONAL LABORATORIES LTD | Director/Miembro de la Junta | 08/11/2024 |
Novo Nordisk Pharma Ltd.
Novo Nordisk Pharma Ltd. Pharmaceuticals: MajorHealth Technology Produces drugs and insulins | Presidente | 01/01/2007 |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
The University of Sydney
The University of Sydney Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novo Nordisk Pharma Ltd.
Novo Nordisk Pharma Ltd. Pharmaceuticals: MajorHealth Technology Produces drugs and insulins | Health Technology |
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd. Medical/Nursing ServicesHealth Services Provides biological research and drug discovery services | Health Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.